Neuphoria Therapeutics Inc. (NEUP) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Shareholders held on December 12, 2025. Neuphoria Therapeutics Inc., a Delaware corporation, is an emerging growth company with its principal executive offices in Burlington, Massachusetts. The filing details the voting outcomes for four proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results rather than financial performance.
Material Changes and Voting Results
Of the 2,357,613 shares outstanding, 937,447 shares (39.76%) were present and entitled to vote. The results for the four proposals were as follows:
- Proposal 1 (Election of Directors): Peter Miles Davies and David Wilson were elected as Class I directors. Stephen Doberstein and Kimberly Smith were not elected, as the majority of votes were withheld for both nominees.
- Proposal 2 (Auditor Ratification): Shareholders approved the ratification of Wolf & Company P.C. as the independent registered public accounting firm for the fiscal year ending June 30, 2026.
- Proposal 3 (Executive Compensation): Shareholders approved the non-binding advisory vote on the compensation of named executive officers.
- Proposal 4 (Compensation Vote Frequency): Shareholders voted to hold the advisory vote on executive compensation every three years.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document serves strictly as a record of the shareholder meeting outcomes.
Key Facts for Investor Verification
- Two director nominees (Stephen Doberstein and Kimberly Smith) failed to secure a majority of votes cast, resulting in their non-election.
- Shareholder participation was approximately 40% of outstanding shares.
- The company has selected a three-year frequency for future executive compensation advisory votes.
- Wolf & Company P.C. has been ratified as the auditor for the fiscal year ending June 30, 2026.